Search for: "Rivas v. State" Results 101 - 115 of 115
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
2 Sep 2008, 5:17 pm
State of Tennessee, No. 06-6208 In civil rights suit alleging that city police discriminated against plaintiffs in violation of the Ame [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
11 Nov 2021, 8:08 am by Dan Bressler
” “‘Within days’ of the Sept. 19, 2019, receipt of the fourth letter, Houston and Rivas ran it by Reed Smith’s in-house counsel and the California State Bar’s ethics hotline, the panel said. [read post]
29 Nov 2017, 4:23 pm by Jeff Kern and Kate Ross*
The annual report states that under Clayton, pursuit of individuals will be the rule rather than the exception.[12] One justification for this strategy is deterrence. [read post]
1 Dec 2017, 2:55 pm by Jeff Kern and Kate Ross*
The annual report states that under Clayton, pursuit of individuals will be the rule rather than the exception.[12] One justification for this strategy is deterrence. [read post]
7 Mar 2008, 2:00 am
: (IPBiz), US: Proposals for the approval of generic biologics under consideration: (Pharmacapsules@Gowlings), US: A paradigm shift in obviousness for pharma, biotech: (IP Law360), US: USPTO’s Bruce Kisliuk addresses ACI Pharma/biotech patent claim drafting and prosecution conference: (Patent Docs), US: New bill to provide biotech companies Sarbanes-Oxley relief: (California Biotech Law Blog), US: Biotech and pharma companies spent millions on lobbying in 2007: (Patent… [read post]
21 Nov 2022, 10:42 am by Trachtman
”[2] Explicitly, the negotiations exclude issues related to market access, investment protection and investor-state dispute settlement.[3] While the text of the Agreement as it stood in November 2022 is not publicly available, its main elements are listed in the box accompanying this article, and it has been described in a relatively recent publication.[4]    Box. [read post]
21 Nov 2022, 10:42 am by Trachtman
”[2] Explicitly, the negotiations exclude issues related to market access, investment protection and investor-state dispute settlement.[3] While the text of the Agreement as it stood in November 2022 is not publicly available, its main elements are listed in the box accompanying this article, and it has been described in a relatively recent publication.[4]    Box. [read post]